Barriers to Antiretroviral Adherence for Patients Living with HIV Infection and AIDS in Botswana

Journal of Acquired Immune Deficiency Syndromes

Volumn 34, Issue 3, 2003, Pages 281-288

  Weiser, Sheri ^c,d,e   Wolfe, William ^c,d   Bangsberg, David ^a   Thior, Ibou ^b   Gilbert, Peter ^b   Makhema, Joseph ^b   Kebaabetswe, Poloko ^b   Dickenson, Dianne ^b   Mompati, Kgosidialwa ^b   Essex, Max ^c   Marlink, Richard ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BOTSWANA HARVARD AIDS INSTITUTE PARTNERSHIP   (Botswana)

^c Harvard AIDS Institute   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

Adherence; Africa; Botswana; Compliance; Highly active antiretroviral therapy; Treatment barriers

Indexed keywords

ANTIRETROVIRUS AGENT; HYDROXYUREA; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; FEMALE; HEALTH CARE COST; HEALTH CARE PERSONNEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERVIEW; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUESTIONNAIRE; SELF REPORT; SIDE EFFECT;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; BOTSWANA; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; EDUCATIONAL STATUS; FEMALE; HEALTH PERSONNEL; HIV-1; HUMANS; INTERVIEWS; MALE; MARITAL STATUS; MIDDLE AGED; OCCUPATIONS; PATIENT COMPLIANCE; QUESTIONNAIRES;

EID: 0242496506     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200311010-00004     Document Type: Article

References (31)

1. Report on the global HIV/AIDS epidemic 2002. Joint United Nations Programme on HIV/AIDS. 14th International Conference of AIDS, Barcelona, July 7-12, 2002.
2. Tarantola D. Current HIV/AIDS Trends in the World. National Conference on HIV/AIDS in Botswana. Conference Report, August 6-7 1997, AIDS/STD Unit, Ministry of Health, Gaborone, Botswana.
3. National AIDS Council Publication. Botswana HIV and AIDS. Second Medium Term Plan. 1997-2002. Ministry of Health, Republic of Botswana.
4. Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis. 2000;30(suppl 2):S171-S176.
5. Chesney MA, Ickovics J, Hecht FM, et al. Adherence: a necessity for successful HIV combination therapy. AIDS. 1999;13(suppl A): S271-S278.
6. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;14:357-366.
7. McNabb J, Ross JW, Abriola K, et al. Adherence to highly active antiretroviral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic. Clin Infect Dis. 2001;33:700-705.
8. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30.
9. Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts Progression to AIDS. AIDS. 2001;15:1181-1183.
10. Hogg RS, Heath K, Bangsberg D, et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS. 2002;16:1051-1058.
11. DeOlalla P, Knobel H, Carmona A, et al. Impact of adherence on highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr. 2001;30:105-110.
12. Stephenson J. AIDS researchers target poor adherence. JAMA. 1999;281:1069.
13. Vanhove GF, Schapiro JM, Winters MA, et al. Patient compliance and drug failure in protease inhibitor monotherapy. JAMA. 1996;276:1955-1956.
14. Harries AD, Nyangulu DS, Hargreaves NJ, et al. Preventing antiretroviral anarchy in sub-Saharan Africa. Lancet. 2001;358:410-414.
15. Popp D, Fisher JD. First do no harm: a call for emphasizing adherence and HIV prevention interventions in active antiretroviral therapy programs in the developing world. AIDS. 2002;16:676-678.
16. Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV Clinical Trials: The AACTG Adherence Instruments Patient Care Committee and Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care. 2000;12:255-266.
17. Stephenson BJ, Rowe BH, Haynes RB, et al. Is this patient taking the treatment as prescribed? JAMA. 1993;269:2779-2781.
18. Chesney MA, Morin M, Sherr L. Adherence to HIV combination therapy. Soc Sci Med. 2000;50:1599-1605.
19. Murri R, Ammassari A, Gallicano K, et al. Patient-reported nonadherence to HAART is related to protease inhibitor levels. J Acquir Immune Defic Syndr. 2000;24:123-128.
20. Woolson RF. Statistical Methods for the Analysis of Biomedical Data. New York: John Wiley & Sons; 2002.
21. Nieuwkerk PT, Sprangers MA, Burger DM, et al. Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Arch Intern Med. 2001;161:1962-1968.
22. Wegner N, Gifford A, Liu H, et al. Patient characteristics and attitudes associated with antiretroviral adherence. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, January 1999.
23. Byakika-Tusiime J, Oyugi JH, Tumwikirize WA, et al. Ability to purchase and secure stable therapy are significant predictors of non-adherence to antiretroviral therapy in Kampala Uganda [abstract]. 10th Conference on Retroviruses and Opportunistic Infections, Boston, February 2003.
24. Orrell C, Bangsberg D, Badri M, et al. Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS. 2003;17:1369-1375.
25. Laurent C, Diakhate N, Fatou N, et al. The Senegalese government's highly active antiretroviral therapy initiative: 18-month follow-up. AIDS. 2002;16:1361-1370.
26. Laurent C, Fatou N, Gueye NF, et al. Long-term follow-up of a cohort of patients under HAART in Senegal [abstract]. 10th Conference on Retroviruses and Opportunistic Infections, Boston, February 2003.
27. Ammassari A, Murri R, Pezzotti P, et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr. 2001;28:445-449.
28. Sumartojo E. When tuberculosis treatment fails: a social behavioral account of patient adherence. Am Rev Respir Dis. 1993;147:1311-1320.
29. Amsten JH, Demas PA, Farzadegan H, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users. Comparison of self-report and electronic monitoring. Clin Infect Dis. 2001;33:1417-1423.
30. Bangsberg DR, Hecht FM, Clague H, et al. Provider assessment of adherence to HIV antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;26:435-442.
31. Haubrich RH, Little SJ, Currier JS, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. AIDS. 1999;13:1099-1107.